Wall Street brokerages expect that Spark Therapeutics Inc (NASDAQ:ONCE) will announce sales of $4.75 million for the current quarter, according to Zacks. Four analysts have provided estimates for Spark Therapeutics’ earnings. The highest sales estimate is $15 million and the lowest is $1.3 million. Spark Therapeutics reported sales of $1.29 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 268.2%. The company is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, May 9th.
According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $4.75 million for the current fiscal year, with estimates ranging from $5.2 million to $45.06 million. For the next year, analysts expect that the company will report sales of $140.14 million per share, with estimates ranging from $38.56 million to $251.3 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.30) by $0.40. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.35 million. During the same quarter in the prior year, the company earned ($0.95) earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis.
ONCE has been the topic of a number of research reports. Stifel Nicolaus reissued a “buy” rating and set a $76.00 target price on shares of Spark Therapeutics in a report on Monday, April 10th. Vetr lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 target price on the stock. in a report on Tuesday, January 10th. BMO Capital Markets reissued an “outperform” rating and set a $69.00 target price on shares of Spark Therapeutics in a report on Friday, April 7th. Jefferies Group LLC reissued a “hold” rating and set a $57.00 target price on shares of Spark Therapeutics in a report on Tuesday, January 10th. Finally, JPMorgan Chase & Co. set a $82.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $68.31.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up 3.80% during trading on Thursday, reaching $60.17. 593,243 shares of the company traded hands. The firm’s market capitalization is $1.87 billion. Spark Therapeutics has a 12-month low of $31.28 and a 12-month high of $65.99. The company has a 50 day moving average price of $54.28 and a 200 day moving average price of $55.85.
In other news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $55.18, for a total value of $551,800.00. Following the transaction, the chief financial officer now owns 4,398 shares in the company, valued at approximately $242,681.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anand Mehra sold 35,347 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $65.03, for a total transaction of $2,298,615.41. The disclosure for this sale can be found here. Insiders sold a total of 226,143 shares of company stock worth $14,356,283 in the last 90 days. Corporate insiders own 9.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of Spark Therapeutics during the fourth quarter worth about $883,000. Endurant Capital Management LP purchased a new position in shares of Spark Therapeutics during the third quarter worth about $348,000. Baker BROS. Advisors LP purchased a new position in shares of Spark Therapeutics during the third quarter worth about $79,180,000. Rock Springs Capital Management LP increased its position in shares of Spark Therapeutics by 2.5% in the third quarter. Rock Springs Capital Management LP now owns 625,000 shares of the biotechnology company’s stock worth $37,538,000 after buying an additional 15,000 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Spark Therapeutics by 32.8% in the third quarter. Ameriprise Financial Inc. now owns 129,627 shares of the biotechnology company’s stock worth $7,786,000 after buying an additional 32,023 shares during the period. Hedge funds and other institutional investors own 83.97% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.